Simcere Pharmaceutical Group, a China company that makes branded generic and proprietary pharmaceuticals, now controls a majority 50.77% of its vaccine subsidiary, Jiangsu Yanshen Biological Technology Stock Co., Ltd. Simcere bought its original 37.5% stake in Jiangsu Yanshen in May 2009. Jiangsu Yanshen has received orders for 6.3 million doses of its H1N1 flu vaccine from China's government. More details...

Stock Symbol: (NYSE: SCR)